Phase I clinical trial of bortezomib in
โ
David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 114 KB
๐ 2 views
## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and doseโlimiting toxicities (DLTs) of bortezomib in combi